ASKA Pharmaceutical Holdings (4886) Fundamentals 2026 — P/E 11.6x, Revenue Analysis | SniperIQ
ASKA Pharmaceutical Holdings (4886) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥63.1B, trading at ¥2223.00 on the JPX. This SniperIQ fundamentals page covers ASKA Pharmaceutical Holdings's valuation (P/E 11.6x, P/B 0.9x), profitability (net margin 7.6%), revenue (¥71.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ASKA Pharmaceutical Holdings's market cap?
ASKA Pharmaceutical Holdings (4886) has a market capitalization of approximately ¥63.1B, trading at ¥2223.00 on the JPX. Market cap moves with the live share price.
What is ASKA Pharmaceutical Holdings's P/E ratio?
ASKA Pharmaceutical Holdings's trailing twelve-month P/E ratio is 11.6x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ASKA Pharmaceutical Holdings?
ASKA Pharmaceutical Holdings runs a net profit margin of 7.6%, a gross margin of 48.0%, and an operating margin of 8.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ASKA Pharmaceutical Holdings generate?
ASKA Pharmaceutical Holdings reported revenue of ¥71.1B for fiscal year 2025, with net income of ¥5.4B and earnings per share (EPS) of 191.1. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ASKA Pharmaceutical Holdings pay a dividend?
ASKA Pharmaceutical Holdings offers a trailing dividend yield of about 2.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is ASKA Pharmaceutical Holdings financially healthy?
ASKA Pharmaceutical Holdings carries a debt-to-equity ratio of 0.16x and a current ratio of 2.76x, with a market beta of 0.45. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ASKA Pharmaceutical Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ASKA Pharmaceutical Holdings (4886) the key facts are: market cap ¥63.1B, P/E 11.6x, revenue ¥71.1B, 52-week range 1920-3045. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ASKA Pharmaceutical Holdings's full fundamentals live
Get ASKA Pharmaceutical Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.